Survivin as a Therapeutic Target for the Treatment of Human Cancer

Cancers (Basel). 2024 Apr 27;16(9):1705. doi: 10.3390/cancers16091705.

Abstract

Survivin was initially identified as a member of the inhibitor apoptosis (IAP) protein family and has been shown to play a critical role in the regulation of apoptosis. More recent studies showed that survivin is a component of the chromosome passenger complex and acts as an essential mediator of mitotic progression. Other potential functions of survivin, such as mitochondrial function and autophagy, have also been proposed. Survivin has emerged as an attractive target for cancer therapy because its overexpression has been found in most human cancers and is frequently associated with chemotherapy resistance, recurrence, and poor survival rates in cancer patients. In this review, we discuss our current understanding of how survivin mediates various aspects of malignant transformation and drug resistance, as well as the efforts that have been made to develop therapeutics targeting survivin for the treatment of cancer.

Keywords: apoptosis; cancer; mitosis; survivin.

Publication types

  • Review

Grants and funding

This research received no external funding.